| Name | Title | Contact Details |
|---|
Rheonix, Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. As scientific knowledge evolves, so does the need for new diagnostic technology to simplify processes and enhance innovation. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy to use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in-between.
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
MitoSciences Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.